Find-A-Study

Six weeks of daily rifapentine vs. a comparator arm of 12-16 week rifamycin-based treatment of latent M. tuberculosis infection: assessment of safety, tolerability and effectiveness - ASTERoiD

Purpose

Category

Immune System
Infections / Infectious Diseases

IRB Number: 20180194HU
NCT Number: -
Open to Enrollment: Yes
Sponsor: -

Study Contact

Local Recruitment Point of Contact
Melissa Engle
(210) 617-5300
englem2@uthscsa.edu

Overall Recruitment Point of Contact
Jose Cadena Zuluaga
(210) 567-4666
cadenazuluag@uthscsa.edu

Principal Investigator
Jose Cadena Zuluaga

Regulatory Point of Contact
Jose Cadena Zuluaga
(210) 567-4666
cadenazuluag@uthscsa.edu

Regulatory Point of Contact
Melissa Engle
(210) 617-5300
englem2@uthscsa.edu

Eligibility

Eligible Ages
Eligible Genders
Accepts Healthy Volunteers: No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups